Evaluation of bronchodilation induced by beta-adrenergic agents in COPD patients. -Three-dimensional CT Image analysis-

Evaluation of bronchodilation induced by beta-adrenergic agents in COPD patients. -Three-dimensional CT Image analysis- - Evaluation of bronchodilation induced by beta-adrenergic agents in COPD patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002668

Enrollment

Registered

2009-10-26

Start date

2009-10-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Salmeterol/Fluticasone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: Patients with signs of any other major pulmonary diseases such as bronchial asthma, pulmonary fibrosis, and pulmonary cancer according to chest radiographs, CT and other laboratory findings. Patients judged to be inappropriate by respirologists

Design outcomes

Primary

Measure	Time frame
The relationship between change in airway caliber and pulmonary function parameter induced by inhaled Salmeterol/Fluticasone.	—

Secondary

Measure	Time frame
Pulmonary function parameters Airway inner luminal area Airway wall area percent	—

Countries

Japan

Contacts

Public ContactMasaru Hasegawa

Hokkaido University Hospital, First Department of Medicine Department of Internal Medicine, Division of Respiratory Medicine

masaruh@med.hokudai.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026